医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Increasing Awareness of Bone Health Will Fast-track the Osteoporosis Drugs Market in APAC Region by 2019: TechNavio

2014年12月10日 AM01:45
このエントリーをはてなブックマークに追加


 

LONDON

TechNavio has announced the publication of a new market research report on the Osteoporosis Drugs Market in APAC Region, which is expected to grow at a CAGR of 4.73 percent from 2015-2019.

According to the new report, enhanced patient and physician awareness has been leading to greater drug penetration. Additionally, institutions like the National Osteoporosis Foundation are dedicated to the prevention of osteoporosis and fractures.

“In the US, May is celebrated as National Osteoporosis Awareness and Prevention month. Such initiatives are increasing the awareness of bone health among the general population,” says Faisal Ghaus, Vice President of TechNavio.

Furthermore, the paradigm shift from antiresorptive therapies to anabolic drugs is also expected to propel the overall market growth. Treatments for osteoporosis, which haven’t evolved much in the past 20 years, will see a major overhaul with the launch of new efficacious and safe anabolic treatments.

“Three late-stage pipeline products, romosozumab, BA-058 and oral PTH have been found to be highly effective in increasing bone mineral density (BMD) by almost double the amount as compared to current treatment options,” says Ghaus.

Key Information Covered in the Report:

  • Market segmentation, size and forecast through 2019
  • Market Growth Drivers:
  • Market Challenges:
  • Market Trends:
    • Increasing Awareness of Bone Health Education
    • For a full detailed list, view our report.
  • Key Vendors:
    • Amgen Inc.
    • Eli Lilly & Co.
    • Merck & Co. Inc.
    • Novartis AG
  • Other Prominent Vendors:
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Jiangsu Hengrui Medicine
    • Pfizer

TechNavio currently has more than 3000 market research reports on a huge range of topics, including 50+ reports on the osteoporosis drugs market:

If you are interested in more information, please contact our media team at media@technavio.com.

CONTACT

TechNavio Research
Jes Ellacott
US: +1 630-333-9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作